SCYNEXIS Inc (SCYX) is Upgraded by WBB Securities to Strong Buy, Price Target at $8

SCYNEXIS Inc (SCYX) was Upgraded by WBB Securities to ” Strong Buy” and the brokerage firm has set the Price Target at $8. Earlier the firm had a rating of “Buy ” on the company shares. WBB Securities advised their investors in a research report released on Oct 7, 2016.

Many Wall Street Analysts have commented on SCYNEXIS Inc. SCYNEXIS Inc was Resumed by Brean Capital to “Buy” on Oct 3, 2016. Guggenheim Initiated SCYNEXIS Inc on Aug 17, 2016 to “Buy”, Price Target of the shares are set at $15.Shares were Reiterated by Needham on Aug 9, 2016 to “Buy” and Lowered the Price Target to $ 10 from a previous price target of $16 .

SCYNEXIS Inc closed down -0.06 points or -1.32% at $4.49 with 5,76,451 shares getting traded on Tuesday. Post opening the session at $4.51, the shares hit an intraday low of $4.27 and an intraday high of $4.589 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

In a different news, on Sep 16, 2016, Patrick Machado (director) purchased 40,000 shares at $2.94 per share price. According to the SEC, on Jul 1, 2016, Gonzalez David Angulo (Chief Medical Officer) purchased 36,950 shares at $2.20 per share price. On Jun 28, 2016, Marco Taglietti (CEO) purchased 100,000 shares at $2.39 per share price, according to the Form-4 filing with the securities and exchange commission.

SCYNEXIS Inc. is a pharmaceutical company. The Company is engaged in the discovery development and commercialization of anti-infectives. It also provides contract research and development services primarily in the field of animal health. Its lead product candidate SCY-078 is an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. SCY-078 has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species including drug resistant strains. In addition the Company has additional compounds similar to SCY-078. The Company has developed a platform for cyclophilin inhibitors. Its cyclophilin inhibitor platform has two clinical stage compounds: SCY-635 which is a cyclophilin inhibitor for the treatment of dog dry eye and SCY-641 which is a cyclophilin inhibitor with activity similar to cyclosporine for the treatment of viral diseases in humans.


Leave a Reply

SCYNEXIS Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on SCYNEXIS Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.